[Side effects and pharmacovigilance of GLP1 agonists]. [PDF]
Maria Tablado MA.
europepmc +1 more source
[Comment on the article: "Epidemiological and clinical aspects of Guillain-Barré syndrome, 2012-2022"]. [PDF]
Gómez-Madrigal D.
europepmc +1 more source
[Impulse control disorder: patients with pituitary adenomas and dopaminergic agonists]. [PDF]
Barreras-Ruíz A +4 more
europepmc +1 more source
Challenges in the management of alcohol-associated liver disease in Latin America
Francisco Idalsoaga +4 more
doaj +1 more source
[The Usefulness of Neuromodulators in Clinical Practice: The Gastroenterologist's Viewpoint]. [PDF]
García-Zermeño KR +3 more
europepmc +1 more source
[Anti-obesity drugs and potential changes in the epidemiology of this condition and in cardiovascular risk factors]. [PDF]
Cuatrecasas G.
europepmc +1 more source
[Gastrointestinal manifestations and liver disorders in patients with COVID-19]. [PDF]
Vázquez-Cruz E +3 more
europepmc +1 more source
[Drug Excipients. Necessary, but not Harmless]. [PDF]
López Alarcón MD +2 more
europepmc +1 more source
[Multisystem inflammatory syndrome in a young infant with lymphocytosis and reactive thrombocytosis post COVID-19: Case report]. [PDF]
Vera-Rodríguez HA +5 more
europepmc +1 more source

